生物制剂在银屑病和特应性皮炎中的应用与免疫表型转换机制研究进展

doi:10.35541/cjd.20220795

Abstract

Abstract: 【Abstract】 While biologic therapies have been successfully applied in the treatment of psoriasis and atopic dermatitis, unique phenomena of immunophenotypic switching have also been constantly reported. This review summarizes the current status and mechanisms of immunophenotypic switching among patients with psoriasis or atopic dermatitis during the treatment with biologic therapies, in order to fully understand this new abnormal immune reaction.

Key words: Psoriasis, Dermatitis, atopic, Biological agents, Eczema, Immunophenotypic switching

Ye Hui, Xue Rujun, Zhang Xibao. Application of biological therapies and mechanisms of immunophenotypic switching in psoriasis and atopic dermatitis[J]. Chinese Journal of Dermatology,2024,e20220795. doi:10.35541/cjd.20220795

References ［45］

［1］	Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL⁃17 treatment: a case series and review of the literature［J］. Expert Opin Biol Ther, 2020,20（6）:665⁃672. doi: 10.1080/14712598.2020.1727439.
［2］	Al⁃Janabi A, Foulkes AC, Mason K, et al. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review［J］. J Eur Acad Dermatol Venereol, 2020,34（7）:1440⁃1448. doi: 10.1111/jdv.16246.
［3］	Davaine AC, Saraux A, Prigent S, et al. Cutaneous events during treatment of chronic inflammatory joint disorders with anti⁃tumour necrosis factor alpha: a cross⁃sectional study［J］. J Eur Acad Dermatol Venereol, 2008,22（12）:1471⁃1477. doi: 10.1111/j.1468⁃3083.2008.02935.x.
［4］	Napolitano M, Scalvenzi M, Fabbrocini G, et al. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series［J］. Dermatol Ther, 2019,32（6）:e13142. doi: 10.1111/dth.13142.
［5］	Jaulent L, Staumont⁃Sallé D, Tauber M, et al. De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort［J］. J Eur Acad Dermatol Venereol, 2021,35（4）:e296⁃296e297. doi: 10.1111/jdv.17050.
［6］	Flanagan KE, Pupo Wiss IM, Pathoulas JT, et al. Dupilumab⁃induced psoriasis in a patient with atopic dermatitis and alopecia totalis: a case report and literature review［J］. Dermatol Ther, 2022,35（2）:e15255. doi: 10.1111/dth.15255.
［7］	Tracey EH, Elston C, Feasel P, et al. Erythrodermic presentation of psoriasis in a patient treated with dupilumab［J］. JAAD Case Rep, 2018,4（7）:708⁃710. doi: 10.1016/j.jdcr.2018.05.014.
［8］	Czarnowicki T, He H, Krueger JG, et al. Atopic dermatitis endotypes and implications for targeted therapeutics［J］. J Allergy Clin Immunol, 2019,143（1）:1⁃11. doi: 10.1016/j.jaci. 2018.10.032.
［9］	Dai YX, Tai YH, Chang YT, et al. Bidirectional association between psoriasis and atopic dermatitis: a nationwide population⁃based cohort study［J］. Dermatology, 2021,237（4）:521⁃527. doi: 10.1159/000514581.
［10］	Chen WY, Chen SC, Hsu SY, et al. Annoying psoriasis and atopic dermatitis: a narrative review［J］. Int J Mol Sci, 2022,23（9）:4898. doi: 10.3390/ijms23094898.
［11］	Langan SM, Irvine AD, Weidinger S. Atopic dermatitis［J］. Lancet, 2020,396（10247）:345⁃360. doi: 10.1016/S0140⁃6736（20）31286⁃1.
［12］	Yang G, Seok JK, Kang HC, et al. Skin barrier abnormalities and immune dysfunction in atopic dermatitis［J］. Int J Mol Sci, 2020,21（8）:2867. doi: 10.3390/ijms21082867.
［13］	Tsai YC, Tsai TF. Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes［J］. Int J Mol Sci, 2022,23（10）:5518. doi: 10.3390/ijms23105518.
［14］	Newsom M, Bashyam AM, Balogh EA, et al. New and emerging systemic treatments for atopic dermatitis［J］. Drugs, 2020,80（11）:1041⁃1052. doi: 10.1007/s40265⁃020⁃01335⁃7.
［15］	de Alcantara CC, Reiche E, Simão A. Cytokines in psoriasis［J］. Adv Clin Chem, 2021,100:171⁃204. doi: 10.1016/bs.acc.2020. 04.004.
［16］	Safa G, Paumier V. Psoriasis induced by dupilumab therapy［J］. Clin Exp Dermatol, 2019,44（3）:e49⁃e50. doi: 10.1111/ced. 13901.
［17］	Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses［J］. J Exp Med, 2007,204（13）:3183⁃3194. doi: 10.1084/jem.20071094.
［18］	Al⁃Janabi A, Foulkes AC, Griffiths C, et al. Paradoxical eczema in patients with psoriasis receiving biologics: a case series［J］. Clin Exp Dermatol, 2022,47（6）:1174⁃1178. doi: 10.1111/ced. 15130.
［19］	Dumont⁃Berset M, Laffitte E, Gerber C, et al. Eczematous drug eruption after infliximab［J］. Br J Dermatol, 2004,151（6）:1272⁃1273. doi: 10.1111/j.1365⁃2133.2004.06282.x.
［20］	Senner S, Eicher L, Aszodi N, et al. Psoriasis in dupilumab⁃treated atopic dermatitis［J］. Hautarzt, 2020,71（5）:383⁃386. doi: 10.1007/s00105⁃020⁃04565⁃8.
［21］	Pouillot A, Dayan N, Polla AS, et al. The stratum corneum: a double paradox［J］. J Cosmet Dermatol, 2008,7（2）:143⁃148. doi: 10.1111/j.1473⁃2165.2008.00379.x.
［22］	Lee E, Min K, Ahn H, et al. Potential therapeutic skin microbiomes suppressing Staphylococcus aureus⁃derived immune responses and upregulating skin barrier function⁃related genes via the AhR signaling pathway［J］. Int J Mol Sci, 2022,23（17）:9551. doi: 10.3390/ijms23179551.
［23］	Munera⁃Campos M, Ballesca F, Richarz N, et al. Paradoxical eczematous reaction to ixekizumab［J］. J Eur Acad Dermatol Venereol, 2019,33（1）:e40⁃e42. doi: 10.1111/jdv.15156.
［24］	Kimura R, Sugita K, Yamamoto O. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab⁃induced eczema［J］. Eur J Dermatol, 2020,30（6）:732⁃734. doi: 10.1684/ejd.2020.3904.
［25］	Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL⁃17 treatment: a case series and review of the literature［J］. Expert Opin Biol Ther, 2020,20（6）:665⁃672. doi: 10.1080/14712598.2020.1727439.
［26］	Danset M, Hacard F, Jaulent C, et al. Brodalumab⁃associated generalized eczematous eruption in a difficult⁃to⁃treat psoriasis patient: management without brodalumab withdrawal［J］. Eur J Dermatol, 2020,30（6）:741⁃743. doi: 10.1684/ejd.2020.3910.
［27］	李妍, 李明, 李邻峰. 湿疹样损害与银屑病样损害的免疫漂移［J］. 皮肤科学通报, 2023,40（1）:37⁃43.
［28］	Ishiuji Y, Umezawa Y, Asahina A, et al. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases［J］. J Dermatol, 2018,45（6）:732⁃734. doi: 10.1111/1346⁃8138. 14295.
［29］	Nakajima K, Abe T, Saji R, et al. Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy［J］. Allergol Int, 2020,64（4）:382⁃383. doi: 10.1016/j.jinf. 2020.08.021.
［30］	Hattori N, Koike Y, Murota H. Treatment with an interleukin⁃17 inhibitor resulted in complete remission of psoriasis and flare⁃up of atopic dermatitis［J］. J Dermatol, 2022,49（5）:e173⁃e174. doi: 10.1111/1346⁃8138.16308.
［31］	Burlando M, Cozzani E, Russo R, et al. Atopic⁃like dermatitis after secukinumab injection: a case report［J］. Dermatol Ther, 2019,32（1）:e12751. doi: 10.1111/dth.12751.
［32］	Koschitzky M, Tan K, Noliza Encarnacion MR, et al. Eczematous reactions to psoriasis biologics treated with dupilumab: a case series［J］. JAAD Case Rep, 2021,11:29⁃32. doi: 10.1016/j.jdcr. 2021.03.006.
［33］	Mendes Roncada EV, Brambilla VR, Freitas Filitto B, et al. Atopic dermatitis as a paradoxical effect of secukinumab for the treatment of psoriasis［J］. Case Rep Dermatol, 2021,13（2）:336⁃339. doi: 10.1159/000513467.
［34］	Paolino G, Di Nicola MR, Brianti P, et al. New onset atopic dermatitis and psoriasis in the same patients under biologic treatments: the role of systemic treatments as a possible trigger［J］. Dermatol Ther, 2022,35（11）:e15814. doi: 10.1111/dth.15814.
［35］	Bose R, Beecker J. Dyshidrotic eczema in two patients on secukinumab for plaque psoriasis: a case report［J］. SAGE Open Med Case Rep, 2020,8:2050313X20904561. doi: 10.1177/2050313X20904561.
［36］	Johnson MC, Bowers NL, Strowd LC. Concurrent atopic dermatitis and psoriasis vulgaris: implications for targeted biologic therapy［J］. Cutis, 2022,109（2）:110⁃112. doi: 10.12788/cutis.0453.
［37］	Fowler E, Silverberg JI, Fox JD, et al. Psoriasiform dermatitis after initiation of treatment with dupilumab for atopic dermatitis［J］. Dermatitis, 2019,30（3）:234⁃236. doi: 10.1097/DER.0000 000000000481.
［38］	Ferrucci S, Tavecchio S, Berti E, et al. Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab［J］. Clin Exp Dermatol, 2020,45（5）:625⁃626. doi: 10.1111/ced.14207.
［39］	D′Ambra I, Babino G, Fulgione E, et al. Psoriasis onset under dupilumab treatment in two patients affected by atopic dermatitis and one patient affected by alopecia areata: clinical and dermoscopic patterns［J］. Dermatol Ther, 2020,33（6）:e14169. doi: 10.1111/dth.14169.
［40］	Parker JJ, Sugarman JL, Silverberg NB, et al. Psoriasiform dermatitis during dupilumab treatment for moderate⁃to⁃severe atopic dermatitis in children［J］. Pediatr Dermatol, 2021,38（6）:1500⁃1505. doi: 10.1111/pde.14820.
［41］	Maiolini VM, Sousa NA, Marsillac PF, et al. Alopecia areata⁃like and psoriasis after dupilumab use for atopic dermatitis［J］. An Bras Dermatol, 2021,96（5）:634⁃636. doi: 10.1016/j.abd.2021. 03.005.
［42］	Mirza FN, Wang A, Ramachandran SM, et al. Dupilumab⁃induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin⁃17A expression: a case report［J］. Br J Dermatol, 2021,185（2）:432⁃434. doi: 10.1111/bjd.20064.
［43］	Jia X, Li C, Wu J, et al. Pustular psoriasis aappearing induced by dupilumab therapy in a patient with atopic dermatitis［J］. J Drugs Dermatol, 2022,21（3）:311⁃312. doi: 10.36849/JDD.6271.
［44］	Zhong X, Li Y, Gao Y, et al. Pustular psoriasis appearing in a Chinese woman treated with dupilumab for atopic dermatitis: a case report［J］. Dermatol Ther, 2022,35（11）:e15851. doi: 10. 1111/dth.15851.
［45］	Fan J, Zhang L, Lu Y, et al. A case of dupilumab⁃induced reverse psoriasis in a patient with atopic dermatitis［J］. Dermatol Ther, 2022,35（4）:e15345. doi: 10.1111/dth.15345.

[1]	Bai Lu, Chu Yan, Liu Yuanyuan, Zhu Caiyong. Treatment of chronic hand eczema [J]. Chinese Journal of Dermatology, 2025, 58(5): 477-480.
[2]	Committee on Psoriasis, Chinese Society of Dermatology. Expert proposal on apremilast for the treatment of psoriasis （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 416-424.
[3]	China Dermatologist Association, Treatment Group, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, National Clinical Research Center for Dermatologic and Immunologic Diseases, Rare Skin Diseases Committee, China Alliance for Rare Diseases. Diagnosis and treatment of bullous pemphigoid: an expert consensus statement （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 405-415.
[4]	Li Ziyu, Lu Yan. Paying attention to severe skin diseases after COVID-19 [J]. Chinese Journal of Dermatology, 2025, 58(4): 378-383.
[5]	Group on Pediatric Dermatology, China Dermatologist Association, Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of pediatric pustular psoriasis in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 297-306.
[6]	He Chunxia, Jin Hongzhong . Principles, current status, challenges and perspectives in the diagnosis and treatment of critical dermatological emergencies [J]. Chinese Journal of Dermatology, 2025, 58(4): 307-314.
[7]	Mu Kui, Guo Hui, Wen Haiquan, Long Hai, Liu Yu, Luo Shuaihantian, Huang Xin, Zhou Xingyu, Xiao Rong, Li Yaping. Efficacy and safety analysis of combined telitacicept in 25 patients with systemic lupus erythematosus based on standard therapy [J]. Chinese Journal of Dermatology, 2025, 58(4): 322-327.
[8]	Li Xiuzhen, Xu Xiulian. Effects of interleukin-23 inhibitors on psoriasis comorbidities [J]. Chinese Journal of Dermatology, 2025, 58(3): 268-272.
[9]	Lianghong Chen Yan SUN Jing-Yu WANG. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2025, 58(3): 266-268.
[10]	Wang Caixia, Xu Fan, Shi Jing, Zhu Hailian, Lu Guiling, Wang Hongmei. Efficacy and safety of omalizumab and dupilumab for the treatment of bullous pemphigoid: a systematic review [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220929-e0220929.
[11]	Xu Zhuohong, Hu Yu, Gu Heng. Role of mesenchymal stem cell-derived exosomes in skin diseases [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220881-e20220881.
[12]	Wang Wenqiu, Li Chengxin, Wang Rui. Biologics for the treatment of psoriasis relapse: current status [J]. Chinese Journal of Dermatology, 2025, 0(3): 20230301-e20230301.
[13]	Zhang Xiaoxu, Luo Suju. Efficacy and safety of upadacitinib in the treatment of six cases of palmoplantar pustulosis [J]. Chinese Journal of Dermatology, 2025, 0(2): 20230772-e20230772.
[14]	Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52.
[15]	Wang Bo, Zheng Jie. Considerations in the treatment of elderly patients with psoriasis and atopic dermatitis using biologics and small-molecule drugs [J]. Chinese Journal of Dermatology, 2025, 58(1): 72-75.

Application of biological therapies and mechanisms of immunophenotypic switching in psoriasis and atopic dermatitis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［45］

Related Articles 15

Metrics

Comments

Recommended 10